Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
-
Exhibit navigating the fight for liberty to open at the Hampton History Museum
-
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
-
CAPREIT to Invest in Canadian Housing Supply with Construction of 170 Residential Suites Within Existing Portfolio
-
Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access
-
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
-
WSP acquires specialist healthcare and life sciences consulting firm Lexica
-
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Filecoin Foundation and Randamu Enable Time-Locked Smart Contracts for the Decentralized Storage Economy
-
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
-
Bitmine Immersion Technologies, Inc. Announces Uplist to NYSE American Stock Exchange
-
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
-
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
-
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
-
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
-
FDA Accepts TransCon® CNP NDA for Priority Review
-
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
-
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
-
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/k
-
Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors
-
Lightbridge Completes Final Experiment Design for Designated ATR Core Position
-
Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
-
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
-
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
-
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Condi
-
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
-
Solésence Expands Debt Facilities to Fuel Growth Initiatives
-
Oportun Issues Letter to Stockholders and Mails Definitive Proxy Materials
-
CareCloud to Present on AI Innovation at Maxim Group’s 2025 Virtual Tech Conference on June 3, 2025
-
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (AS
-
Webus Signs up to $300 Million XRP Treasury Management Agreement with Top-Tier Manager Samara Alpha, Making a Major Step in Its XRP Treasury Strategy
-
Getty Realty Corp. Publishes 2025 Corporate Responsibility Report
-
Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota
-
GRR! Rebrands to Heidelberg Materials
-
Essy Mozaffari, PharmD, MPH, MBA Joins eMAX Health as Head of Real-World Evidence
-
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
-
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
-
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
-
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
-
Freehold Royalties Announces Appointment of Chief Financial Officer
-
Crawford United Corporation Publishes Investor Presentation on Company Website
-
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
-
Xunlei Closes Acquisition of Hupu
-
Ghislain Houle, Executive Vice-President and Chief Financial Officer, to address Wells Fargo 2025 Industrials and Materials Conference
-
JDE Peet’s share buyback periodic update June 2, 2025
-
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
-
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
-
STMicroelectronics Announces Status of Common Share Repurchase Program
